XBIT

XBiotech Inc. (NASDAQ:XBIT) is a biopharmaceutical company founded in 2005 and headquartered in Austin, Texas. The company went public in April 2015 and specializes in discovering, developing, and commercializing True Human monoclonal antibodies for treating various diseases. XBiotech focuses primarily on developing therapies targeting inflammatory and infectious diseases, with a particular emphasis on interleukin-1 alpha (IL-1α) based treatments. The company operates as a clinical-stage biotechnology firm with no current commercial revenue, dedicating its resources to advancing its pipeline of experimental therapies through various stages of development and regulatory approval processes.